Keyphrases
Overall Survival
100%
Older Patients
100%
Cancer-specific
100%
Androgen Deprivation Therapy
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Cancer-specific Survival
60%
Aged 80 Years and over
60%
Confidence Interval
40%
Hazard Ratio
40%
Age Groups
40%
Young Patients
40%
Japan
20%
Overall Survival of Patients
20%
Propensity Score Matching
20%
Low Volume
20%
Survival Outcomes
20%
Retrospective multicenter Study
20%
Prostate Cancer Patients
20%
Prostate Cancer Progression
20%
Relative Survival
20%
Medicine and Dentistry
Overall Survival
100%
Malignant Neoplasm
100%
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Cancer Specific Survival
60%
Hazard Ratio
40%
Disease
20%
Cancer Growth
20%
Propensity Score Matching
20%
Population
20%
Life Table
20%
Relative Survival
20%
Agricultural and Biological Sciences
Androgen
100%
Confidence Interval
66%
Life Table
33%
Population
33%